Experimental drug leads to better blood fat levels in diabetes patients

09/4/2013 | U.S. News & World Report

Type 2 diabetes patients who received the highest doses of an experimental injectable drug called LY attained significant reductions in bad cholesterol and triglyceride rates and increased good cholesterol levels compared with those who received placebo shots, according to a small study in Cell Metabolism. Researchers said the drug, a copy of the fibroblast growth factor 21 hormone, appears to inhibit obesity and improve insulin action.

View Full Article in:

U.S. News & World Report

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC